Viking Therapeutics has moved obesity drug VK2735 into Phase 3. Learn what this early data means for men over 35 managing nutrition and muscle preservation.
In September 2026, Viking Therapeutics advanced its investigational dual GLP-1/GIP receptor agonist VK2735 into Phase 3 trials after Phase 2 data showed approximately 14.7 percent weight loss from baseline. Company management reported these findings during a mid-September healthcare conference, outlining the planned progression of both their injectable and oral weight management programs.
Viking Therapeutics reported that the highest tested weekly injectable dose of 15 mg produced approximately 14.7 percent weight loss from baseline after 13 weeks. According to Viking President and CEO Brian Lian, this promising early result translates to roughly a 15 percent reduction in weight from baseline over the study period. This initial efficacy data has prompted the company to move the program forward into much larger clinical trials. The newly announced Phase 3 injectable program consists of two primary studies designed to evaluate the medication further. The VANQUISH-1 study is enrolling people with obesity, while the VANQUISH-2 study is enrolling people with obesity and type 2 diabetes.
The Phase 3 trials will test weekly subcutaneous VK2735 for 78 weeks, representing a significant extension beyond the 13-week Phase 2 timeline. These longer trials will test doses reaching up to 17.5 mg, compared with a maximum 15-mg dose in the Phase 2 study. The reported titration schedule begins at 1.25 mg for two weeks before increasing to 2.5 mg for four weeks. The dose then rises in 2.5-mg increments at four-week intervals to assess tolerability and efficacy over a sustained period. This extended timeline is crucial because successful obesity treatment is not necessarily defined only by the initial rate of weight loss. The development program is testing both short-term efficacy and long-term durability. The practical question is whether patients can sustain clinically meaningful results over longer periods and with a manageable treatment burden.
Viking is also exploring less-frequent maintenance dosing to potentially reduce the treatment burden for patients over time.
In addition to the injectable medication, Viking is developing an oral formulation of VK2735. The highest 120-mg dose in an earlier Phase 2 trial produced approximately 12 percent weight loss, according to management’s conference presentation. The company plans to move this oral program into Phase 3 in the fourth quarter of 2026. The oral development is expected to trail the injectable program by approximately 12 to 18 months. These parallel developments indicate that Viking views VK2735 as a broader platform rather than only a once-weekly injection.
Traditional gym floor advice often dictates that men should simply cut calories and drastically increase cardiovascular exercise to shed weight quickly. This outdated approach treats all weight loss as identical, ignoring the critical difference between losing fat and losing metabolically active muscle tissue. When appetite drops sharply, relying solely on generic calorie restriction can lead to significant muscle wasting and a weakened physical state. This is especially problematic for men over 35 who naturally face age-related changes in body composition, energy levels and hormonal balance.
Modern clinical guidance for GLP-1 therapies actively contradicts this old cardio-heavy model. The World Health Organization recommends pairing medication with a healthy diet, physical activity and structured behavioral support. This structured approach recognizes that weight loss is complex and requires multifaceted care. Successful medication-assisted weight management requires targeted nutrition and strength training to protect lean mass. The goal is no longer just seeing a lower number on the bathroom scale. It is about maintaining a strong, capable physique while reducing overall body fat safely.
VK2735 is entering Phase 3 during an increasingly competitive obesity-drug market in which companies are pursuing higher efficacy, oral formulations and less-frequent maintenance schedules. A key uncertainty is whether less-frequent dosing can preserve weight loss while maintaining acceptable tolerability. Reporting on the conference presentation identified gastrointestinal tolerability and avoiding gastrointestinal side effects as an important hurdle for monthly treatment protocols. A strong initial response does not automatically prove that every-other-week or monthly dosing will preserve the same level of weight loss.
For a gay man over 35 looking to optimize his strength and body composition, the advancement of VK2735 is an encouraging sign of future options. Both Phase 3 studies are reportedly fully enrolled, with data expected in the second half of 2027. This drug remains in the development stage, and the cited Phase 2 result is promising but highly preliminary. You should not view this investigational medication as an immediate replacement for established health practices. A development-stage medicine can still fail to achieve its efficacy, safety, manufacturing or regulatory objectives. The most useful takeaway is not that a future drug can replace training or nutrition. Current guidance strongly supports combining GLP-1 therapies with healthy eating, physical activity and structured behavioral support.
If you are currently considering a metabolic medication, your daily routine must prioritize muscle preservation above simple calorie deficits. Nutrition and resistance training are particularly relevant during medication-assisted weight loss because reduced appetite can make it harder to consume sufficient protein and total nutrition. A 2026 clinical discussion cited a proposed protein intake of 1.2 to 1.6 grams per kilogram of body weight during active weight loss. While stressing that this is a proposed target rather than a universal prescription for every patient, experts highlight its importance. If your appetite falls substantially during treatment, meal planning should prioritize adequate protein, fiber-rich foods, hydration and micronutrient density. Treating very low food intake as the goal is a mistake that can compromise your health. Finding consistent nutrition strategies will help you maintain energy levels during treatment.
You must also incorporate progressive resistance training into your weekly schedule to protect your lean mass. Resistance training deserves particular attention for people who care about strength, posture, body composition, sexual confidence and physical capability. It is crucial for maintaining an athletic or aesthetically defined look as you age, because experts identify resistance exercise as a major strategy for preserving muscle during weight loss. The same clinical discussion described progressive resistance training as an important tool for preserving muscle mass and strength, with one expert recommending at least two dedicated sessions per week as a minimum starting point. Maintaining this multidimensional physical capability helps protect your male vitality and sexual wellbeing over the long term.
It is critical to understand the limitations of the current clinical data regarding VK2735. The 14.7 percent figure is an early-phase result measured after only 13 weeks, so it should not be presented as the eventual average result of Phase 3 treatment. It also should not be viewed as a guaranteed personal outcome. The Phase 3 trials will use a different dose ceiling and a much longer treatment period than Phase 2, meaning the two studies are not direct comparisons. Furthermore, the 17.5-mg longer-duration arm discussed in recent coverage reportedly included only 15 patients, making any inference about that specific dose highly preliminary. Less-frequent dosing could eventually improve convenience if Viking’s maintenance studies show that weight loss and tolerability can be maintained, but that outcome remains unproven until the study data are reported.
The available reporting does not establish that VK2735 is superior to approved obesity medicines, nor does it establish that its safety or tolerability profile is better than competing GLP-1-based treatments. Results from the Phase 2 injectable study were reported through company management and conference coverage rather than a fully accessible peer-reviewed publication. The current sources lack a complete trial population breakdown, placebo-adjusted result, confidence intervals and adverse-event tables. Additionally, the available sources do not provide enough detail to determine how much of the reported weight reduction represented fat mass versus lean mass.
A sensible clinical conversation should address your medical history, obesity-related risks and medication interactions. You should also discuss gastrointestinal tolerance, mental health and long-term maintenance plans. Such a discussion should avoid focusing only on the fastest scale change. For readers who are already lean or primarily pursuing cosmetic body recomposition, the evidence summarized here should not be extrapolated automatically. The cited Phase 3 populations are people with obesity, including a subgroup with type 2 diabetes. Any use of an obesity medication must be discussed with a qualified clinician, and unauthorized or non-prescribed products should always be avoided. Exploring dedicated longevity and healthy aging resources can help guide these medical conversations.
If you choose to utilize medication for weight management, you must pair your clinical treatment with adequate protein intake and progressive resistance training to protect your lean muscle mass.
When a man over 35 handles his own health decisions, dealing with slower recovery, changes in energy, sleep or physical capability typically becomes a solo project. Once GayFitLab steps in to curate the clinical data, readers receive stylish, practical guidance without the usual medical hype. We help you balance medication considerations with targeted nutrition and strength training to protect your long-term vitality. Explore Resources
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
